{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:27:07Z","timestamp":1789270027444,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ejca.2016.10.006","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T17:15:43Z","timestamp":1478279743000},"page":"127-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients"],"prefix":"10.1016","volume":"69","author":[{"given":"Ignace","family":"Vergote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Gerdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christi","family":"van Asperen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Marth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Stoppa-Lyonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonzalez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2016.10.006_bib1","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2016.10.006_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","article-title":"Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis","volume":"21","author":"Zhong","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2016.10.006_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine Cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2016.10.006_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12325-016-0281-1","article-title":"Selecting patients with ovarian cancer for germline BRCA mutation testing: findings from guidelines and a systematic literature review","volume":"33","author":"Eccles","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.ejca.2016.10.006_bib5","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","article-title":"BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer","volume":"27","author":"Moschetta","year":"2016","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"10.1016\/j.ejca.2016.10.006_bib6","article-title":"Prevalence of somatic mutations in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1 study)","volume":"34","author":"Hahnen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2016.10.006_bib7","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2016.10.006_bib8","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2016.10.006_bib9","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2016.10.006_bib10","doi-asserted-by":"crossref","first-page":"29506","DOI":"10.1038\/srep29506","article-title":"Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients","volume":"6","author":"George","year":"2016","journal-title":"Sci Rep"},{"issue":"Suppl. 5","key":"10.1016\/j.ejca.2016.10.006_bib11","doi-asserted-by":"crossref","first-page":"v20","DOI":"10.1093\/annonc\/mdq161","article-title":"BRCA in breast cancer: ESMO clinical practice guidelines","volume":"21","author":"Balma\u00f1a","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2016.10.006_bib12","series-title":"Genetic\/familial high-risk assessment: breast and Ovarian. Version 2","author":"NCCN","year":"2015"},{"key":"10.1016\/j.ejca.2016.10.006_bib13","series-title":"SGO clinical practice statement: genetic testing for ovarian cancer","year":"2014"},{"key":"10.1016\/j.ejca.2016.10.006_bib14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s00508-015-0814-7","article-title":"AGO Austria recommendations for genetic testing of patients with ovarian cancer","volume":"127","author":"Marth","year":"2015","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.ejca.2016.10.006_bib15","first-page":"65","article-title":"Therapy-orienting testing of BRCA1 and BRCA2 germline mutations in women with ovarian cancer","volume":"9","author":"Claes","year":"2015","journal-title":"Belg J Med Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2016.10.006_bib16","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.14735\/amko2016S9","article-title":"[Recommended extension of indication criteria for genetic testing of BRCA1 and BRCA2 mutations in hereditary breast and ovarian cancer syndrome]","volume":"29","author":"Foretov\u00e1","year":"2016","journal-title":"Klin Onkol"},{"key":"10.1016\/j.ejca.2016.10.006_bib17","series-title":"Care guidelines. Ovarian cancer","year":"2012"},{"key":"10.1016\/j.ejca.2016.10.006_bib18","unstructured":"http:\/\/www.arcagy.org\/arcagy-organisation-et-recherche\/."},{"key":"10.1016\/j.ejca.2016.10.006_bib19","unstructured":"http:\/\/www.ago-online.de\/fileadmin\/downloads\/leitlinien\/ovar\/S3-Ovarialkarzinom-OL-Langversion.pdf."},{"key":"10.1016\/j.ejca.2016.10.006_bib20","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.2217\/fon-2016-0189","article-title":"Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients","volume":"12","author":"Pinto","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2016.10.006_bib21","unstructured":"http:\/\/www.oncoline.nl\/erfelijk-en-familiair-ovariumcarcinoom."},{"key":"10.1016\/j.ejca.2016.10.006_bib22","unstructured":"http:\/\/www.ipolisboa.min-saude.pt\/Default.aspx?Tag=CONTENT&ContentId=9296 Llort G, Chirivella I."},{"key":"10.1016\/j.ejca.2016.10.006_bib23","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/s12094-015-1435-3","article-title":"SEOM clinical guidelines in hereditary breast and ovarian cancer","volume":"17","author":"Llort","year":"2015","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ejca.2016.10.006_bib24","series-title":"Management of epithelial ovarian cancer","author":"Scottish Intercollegiate Guidelines Network (SIGN)","year":"2013"},{"key":"10.1016\/j.ejca.2016.10.006_bib25","series-title":"Clinical commissioning policy: genetic testing for BRCA1 and BRCA2 mutations","author":"NHS England","year":"2015"},{"key":"10.1016\/j.ejca.2016.10.006_bib26","first-page":"1","article-title":"Inherited mutations in women with ovarian carcinoma","author":"Norquist","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2016.10.006_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/GIM.0b013e318032e4ab","article-title":"Prediction of BRCA1\/2 mutation status in patients with ovarian cancer from a hospital based cohort","volume":"9","author":"Jacobi","year":"2007","journal-title":"Genet Med"},{"key":"10.1016\/j.ejca.2016.10.006_bib28","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ejca.2003.09.016","article-title":"One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden","volume":"40","author":"Malander","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2016.10.006_bib29","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1158\/1078-0432.CCR-07-4806","article-title":"BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark","volume":"14","author":"Soegaard","year":"2008","journal-title":"Clin Cancer Rev"},{"key":"10.1016\/j.ejca.2016.10.006_bib30","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario","volume":"98","author":"Risch","year":"2006","journal-title":"Can J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2016.10.006_bib31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1158\/1078-0432.CCR-14-2497","article-title":"Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer","volume":"21","author":"Candido-dos-Reis","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2016.10.006_bib32","doi-asserted-by":"crossref","first-page":"690","DOI":"10.12968\/bjon.2016.25.12.690","article-title":"The integration of BRCA testing into oncology clinics","volume":"25","author":"Percival","year":"2016","journal-title":"Br J Nurs"},{"key":"10.1016\/j.ejca.2016.10.006_bib33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.2013.51.3226","article-title":"Randomized noninferiority trial of telephone versus in-person genetic counselling for hereditary breast and ovarian cancer","volume":"32","author":"Schwartz","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2016.10.006_bib34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2015.11.001","article-title":"Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer","volume":"53","author":"Lambrechts","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2016.10.006_bib35","doi-asserted-by":"crossref","first-page":"s531","DOI":"10.1016\/S0959-8049(15)30050-2","article-title":"Final results of ARIEL2 (part 1): a phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis","volume":"51","author":"Kristeleit","year":"2015","journal-title":"Eur Cancer Congr"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916324893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916324893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T19:58:10Z","timestamp":1536263890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804916324893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":35,"alternative-id":["S0959804916324893"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2016.10.006","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2016.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}